Cargando…
Biodegradable polymer-coated thin strut sirolimus-eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population
BACKGROUND: The number of patients with diabetes mellitus (DM) presenting with coronary artery disease is increasing and accounts for more than 30% of patients undergoing percutaneous coronary interventions (PCI). The biodegradable polymer drug-eluting stents were developed to improve vascular heali...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Via Medica
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078944/ https://www.ncbi.nlm.nih.gov/pubmed/31909473 http://dx.doi.org/10.5603/CJ.a2019.0111 |
_version_ | 1783685133027508224 |
---|---|
author | Gasior, Pawel Gierlotka, Marek Szczurek-Katanski, Krzysztof Osuch, Marcin Roleder, Magda Hawranek, Michal Wojakowski, Wojciech Polonski, Lech |
author_facet | Gasior, Pawel Gierlotka, Marek Szczurek-Katanski, Krzysztof Osuch, Marcin Roleder, Magda Hawranek, Michal Wojakowski, Wojciech Polonski, Lech |
author_sort | Gasior, Pawel |
collection | PubMed |
description | BACKGROUND: The number of patients with diabetes mellitus (DM) presenting with coronary artery disease is increasing and accounts for more than 30% of patients undergoing percutaneous coronary interventions (PCI). The biodegradable polymer drug-eluting stents were developed to improve vascular healing. It was sought herein, to determine 1-year clinical follow-up in patients with DM treated with the thin strut biodegradable polymer-coated sirolimus-eluting stent (BP-SES) versus durable coating everolimus-eluting stent (DP-EES). METHODS: Patients were retrospectively analyzed with DM were treated with either a BP-SES (ALEX™, Balton, Poland, n = 670) or a DP-EES (XIENCE™, Abbott, USA, n = 884) with available 1 year clinical follow-up using propensity score matching. Outcomes included target vessel revascularization (TVR) as efficacy outcome and all-cause death, myocardial infarction, and definite/probable stent thrombosis as safety outcomes. RESULTS: After propensity score matching 527 patients treated with BP-SES and 527 patients treated with DP-EES were selected. Procedural and clinical characteristics were similar between both groups. In-hospital mortality was 3.23% in BP-SES vs. 2.09% in DP-EES group (p = 0.25). One-year follow-up demonstrated comparable efficacy outcome TVR (BP-SES 6.64% vs. DP-EES 5.88%; p = 0.611), as well as similar safety outcomes of all-cause death (BP-SES 10.06% vs. DP-EES 7.59%; p = 0.158), myocardial infarction (BP-SES 7.959% vs. DP-EES 6.83%; p = 0.813), and definite/probable stent thrombosis (BP-SES 1.14% vs. DP-EES 0.76%; p = 0.525). CONCLUSIONS: The thin-strut biodegradable polymer coated, sirolimus-eluting stent demonstrated comparable clinical outcomes at 1-year after implantation to DP-EES. These data support the relative safety and efficacy of BP-SES in diabetic patients undergoing PCI. |
format | Online Article Text |
id | pubmed-8078944 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Via Medica |
record_format | MEDLINE/PubMed |
spelling | pubmed-80789442021-05-10 Biodegradable polymer-coated thin strut sirolimus-eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population Gasior, Pawel Gierlotka, Marek Szczurek-Katanski, Krzysztof Osuch, Marcin Roleder, Magda Hawranek, Michal Wojakowski, Wojciech Polonski, Lech Cardiol J Interventional Cardiology BACKGROUND: The number of patients with diabetes mellitus (DM) presenting with coronary artery disease is increasing and accounts for more than 30% of patients undergoing percutaneous coronary interventions (PCI). The biodegradable polymer drug-eluting stents were developed to improve vascular healing. It was sought herein, to determine 1-year clinical follow-up in patients with DM treated with the thin strut biodegradable polymer-coated sirolimus-eluting stent (BP-SES) versus durable coating everolimus-eluting stent (DP-EES). METHODS: Patients were retrospectively analyzed with DM were treated with either a BP-SES (ALEX™, Balton, Poland, n = 670) or a DP-EES (XIENCE™, Abbott, USA, n = 884) with available 1 year clinical follow-up using propensity score matching. Outcomes included target vessel revascularization (TVR) as efficacy outcome and all-cause death, myocardial infarction, and definite/probable stent thrombosis as safety outcomes. RESULTS: After propensity score matching 527 patients treated with BP-SES and 527 patients treated with DP-EES were selected. Procedural and clinical characteristics were similar between both groups. In-hospital mortality was 3.23% in BP-SES vs. 2.09% in DP-EES group (p = 0.25). One-year follow-up demonstrated comparable efficacy outcome TVR (BP-SES 6.64% vs. DP-EES 5.88%; p = 0.611), as well as similar safety outcomes of all-cause death (BP-SES 10.06% vs. DP-EES 7.59%; p = 0.158), myocardial infarction (BP-SES 7.959% vs. DP-EES 6.83%; p = 0.813), and definite/probable stent thrombosis (BP-SES 1.14% vs. DP-EES 0.76%; p = 0.525). CONCLUSIONS: The thin-strut biodegradable polymer coated, sirolimus-eluting stent demonstrated comparable clinical outcomes at 1-year after implantation to DP-EES. These data support the relative safety and efficacy of BP-SES in diabetic patients undergoing PCI. Via Medica 2021-04-13 /pmc/articles/PMC8078944/ /pubmed/31909473 http://dx.doi.org/10.5603/CJ.a2019.0111 Text en Copyright © 2021 Via Medica https://creativecommons.org/licenses/by-nc-nd/4.0/This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially. |
spellingShingle | Interventional Cardiology Gasior, Pawel Gierlotka, Marek Szczurek-Katanski, Krzysztof Osuch, Marcin Roleder, Magda Hawranek, Michal Wojakowski, Wojciech Polonski, Lech Biodegradable polymer-coated thin strut sirolimus-eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population |
title | Biodegradable polymer-coated thin strut sirolimus-eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population |
title_full | Biodegradable polymer-coated thin strut sirolimus-eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population |
title_fullStr | Biodegradable polymer-coated thin strut sirolimus-eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population |
title_full_unstemmed | Biodegradable polymer-coated thin strut sirolimus-eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population |
title_short | Biodegradable polymer-coated thin strut sirolimus-eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population |
title_sort | biodegradable polymer-coated thin strut sirolimus-eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population |
topic | Interventional Cardiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078944/ https://www.ncbi.nlm.nih.gov/pubmed/31909473 http://dx.doi.org/10.5603/CJ.a2019.0111 |
work_keys_str_mv | AT gasiorpawel biodegradablepolymercoatedthinstrutsirolimuselutingstentversusdurablepolymercoatedeverolimuselutingstentinthediabeticpopulation AT gierlotkamarek biodegradablepolymercoatedthinstrutsirolimuselutingstentversusdurablepolymercoatedeverolimuselutingstentinthediabeticpopulation AT szczurekkatanskikrzysztof biodegradablepolymercoatedthinstrutsirolimuselutingstentversusdurablepolymercoatedeverolimuselutingstentinthediabeticpopulation AT osuchmarcin biodegradablepolymercoatedthinstrutsirolimuselutingstentversusdurablepolymercoatedeverolimuselutingstentinthediabeticpopulation AT roledermagda biodegradablepolymercoatedthinstrutsirolimuselutingstentversusdurablepolymercoatedeverolimuselutingstentinthediabeticpopulation AT hawranekmichal biodegradablepolymercoatedthinstrutsirolimuselutingstentversusdurablepolymercoatedeverolimuselutingstentinthediabeticpopulation AT wojakowskiwojciech biodegradablepolymercoatedthinstrutsirolimuselutingstentversusdurablepolymercoatedeverolimuselutingstentinthediabeticpopulation AT polonskilech biodegradablepolymercoatedthinstrutsirolimuselutingstentversusdurablepolymercoatedeverolimuselutingstentinthediabeticpopulation |